STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

Welcome to our dedicated news page for Atea Pharmaceuticals (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atea Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atea Pharmaceuticals's position in the market.

News
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Rhea-AI Summary
Atea Pharmaceuticals completes enrollment of over 2,200 high-risk patients in SUNRISE-3 trial for bemnifosbuvir monotherapy cohort. Results expected in 2H’24. Fast Track designation by FDA for COVID-19 treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
clinical trial covid-19
-
News
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) reports a 98% SVR4 rate in Phase 2 HCV study, surpassing 1,400 COVID-19 patient enrollment in Phase 3 SUNRISE-3 study. Financial results for Q4 and full year 2023 show strong operational execution and progress in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
earnings
-
News
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) will host a live conference call to report financial results for Q4 and full year 2023, along with a business update on February 28, 2024, at 4:30 p.m. ET. Participants can access the call via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
conferences earnings
News
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) Achieves 98% Sustained Virologic Response in Phase 2 HCV Study and Surpasses 650 Patients Enrollment in Phase 3 COVID-19 Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.29%
Tags
clinical trial covid-19
-
News
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. A live webcast of the presentation will be available on the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences
-
News
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced positive Phase 1 study results for the coadministration of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination was well tolerated and not affected by food or concomitant dosing, indicating a low risk of drug-drug interactions. In vitro data also demonstrated potent antiviral activity against major HCV NS5A and NS5B resistance-associated variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
News
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
AVIR: Atea Pharmaceuticals Reports Progress in COVID-19 and HCV Trials, Financial Results, and Business Update, with Promising Enrollment Trends, Fast Track Designation, and Substantial Progress in Phase 2 Study. The company aims to develop effective treatments for COVID-19 and HCV patients, with an emphasis on delivering new, safe, and well-tolerated oral antivirals for all patients, including those who are the most vulnerable. The company also expects to report several milestones for the SUNRISE-3 trial in 2024, and initial results from the Phase 2 HCV combination trial are expected in early 2024. Atea Pharmaceuticals also provided financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.12%
Tags
earnings
-
News
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) announces participation in investor conferences in November to present a business update, including the Jefferies London Healthcare Conference on November 15 and the 6th Annual Evercore ISI HealthCONx Conference on November 29. Live webcasts will be available on the company's website, with archived webcasts accessible for at least 90 days after the events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
News
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced two upcoming poster presentations at The Liver Meeting 2023, showcasing the potential of bemnifosbuvir and ruzasvir as a novel treatment for hepatitis C virus (HCV). The compounds demonstrate highly potent, pan-genotypic antiviral activity with favorable drug-drug interaction and safety profiles. The presentations will take place on November 10, highlighting the antiviral profiles and lack of pharmacokinetic drug-drug interaction between the compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
News
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
Rhea-AI Summary
Atea Pharmaceuticals, Inc. will host a live conference call and webcast on November 8, 2023, to report financial results for Q3 2023 and provide a business update. Participants can register to access the call and webcast on the company's Investor Relations website. Telephone participants will receive a confirmation email with dial-in details. An archive of the webcast will be available on the company's website for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
conferences earnings
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#3367 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

314.78M
63.74M
9.46%
67.46%
1.98%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.